One day, two AstraZeneca deals

Share this article:

AstraZeneca expanded the footprint of its biologics arm MedImmune on Tuesday with two announcements: first, that it purchased Spirogen, a private biotech, for $440 million, and second that it joined up with ADC Therapeutics to develop two antibody drug conjugate (ADC) programs.

The ADC deal involves trading $20 million for an equity investment in ADC along with milestone payments. The linkage between the two deals is that Auven Therapeutics is the majority stakeholder in both ADC and Spirogen.

The deals follow AZ's August acquisition of Amplimmune as part of an expansive oncology push.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

The Women's Health landscape is ripe with opportunity for pharma marketers. This seven-page eBook offers product managers a guide to capitalizing on the trends, growth areas and unmet needs. Includes alternative channels to engage OB/GYNs and oncologists, and plenty of tips. Click here to access it.

Email Newsletters